Definitions, outcomes, and management of hyperprogression in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors

被引:16
作者
Abbar, B. [1 ]
Castelbajac, V. De [2 ]
Gougis, P. [3 ]
Assoun, S. [4 ]
Pluvy, J. [4 ]
Tesmoingt, C. [5 ]
Theou-Anton, N. [6 ]
Cazes, A. [7 ]
Namour, C. [4 ]
Khalil, A. [8 ]
Gounant, V. [4 ]
Besse, B. [9 ]
Zalcman, G. [4 ]
Brosseau, S. [4 ]
机构
[1] Sorbonne Univ, Bichat Claude Bernard Hosp, AP HP, Dept Thorac Oncol, Paris, France
[2] Univ Paris, St Louis Hosp, AP HP, Breast Dis Ctr, Paris, France
[3] Sorbonne Univ, Pitie Salpetriere Hosp, AP HP,CLIP2Galilee, Dept Pharmacol,Dept Med Oncol,INSERM,CIC 1901 Par, Paris, France
[4] Univ Paris, Bichat Claude Bernard Hosp, AP HP, Dept Thorac Oncol,CIC 1425,INSERM, Paris, France
[5] Bichat Claude Bernard Hosp, AP HP, Dept Clin Pharm, Paris, France
[6] Bichat Claude Bernard Hosp, AP HP, Dept Genet, Paris, France
[7] Univ Paris, Bichat Claude Bernard Hosp, AP HP, Dept Pathol, Paris, France
[8] Univ Hosp Bichat Claude Bernard, AP HP, Dept Radiol, Paris, France
[9] Saclay Univ Villejuif, Inst Gustave Roussy, Dept Canc Med, Villejuif, France
关键词
Non-small-cell lung cancer; Hyperprogressive disease; Immunotherapy; Programmed cell death 1 receptor; Programmed cell death 1 ligand 2 protein; Cytotoxic T-lymphocyte-associated protein 4 antigen; DISEASE PROGRESSION; NIVOLUMAB; IMMUNOTHERAPY; HEAD;
D O I
10.1016/j.lungcan.2020.12.026
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The advent of immune checkpoint inhibitors (ICI) has been a breakthrough in the care of patients with non-small-cell lung cancers (NSCLC). However, physicians are now facing a previously unidentified clinical situation called hyperprogression (HP), which presents as a fast and unexpected increase in tumor burden. HP's existence and specificity to ICIs remains controversial because a widely acknowledged definition is currently lacking. Meanwhile, management remains elusive. Methods: Medical records from all consecutive NSCLC patients who were treated with ICI from 2015 to 2018 were retrospectively analyzed. The HP incidence rate was calculated according to five definitions (tumor growth rate [TGR]ratio, Delta TGR, tumor growth kinetic [TGK], RECIST, and time to treatment failure [TTF]), and the agreement between such definitions was determined. The HP impact on overall survival (OS) was then assessed. The association between HP (defined using the TGRratio definition) and clinical and biological variables was also assessed. Clinical HP management and its impact on outcomes were described. Results: We identified 169 consecutive ICI-treated patients, with potential HP accounting for 11.3 %, 5.7 %, 17.0 %, 9.6 %, and 31.7 % patients, according to TGRratio, Delta TGR, TGK, RECIST, and TTF definitions. Agreement between the different HP definitions was highly heterogeneous (range 29 %-77 %) and globally poor. HP was associated with shorter OS, compared to standard RECIST progressive disease, but this difference only reached statistical significance when using the TTF definition. TGRratio-based HP was significantly associated with hepatic metastases. In TGRratio-based HP patients, neither resuming chemotherapy nor corticosteroids use was associated with statistically significant impact on overall survival. Conclusion: We found fairly heterogeneous HP rates using different definitions. TTF was the only definition leading to significantly worsened OS. Further studies are needed to provide consensus recommendations for the assessment, definition, and management of HP, whose existence is likely real.
引用
收藏
页码:109 / 118
页数:10
相关论文
共 42 条
[1]   Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact? [J].
Adashek, Jacob J. ;
Subbiah, Ishwaria M. ;
Matos, Ignacio ;
Garralda, Elena ;
Menta, Arjun K. ;
Ganeshan, Dhakshina Moorthy ;
Subbiah, Vivek .
TRENDS IN CANCER, 2020, 6 (03) :181-191
[2]   Novel patterns of response under immunotherapy [J].
Borcoman, E. ;
Kanjanapan, Y. ;
Champiat, S. ;
Kato, S. ;
Servois, V. ;
Kurzrock, R. ;
Goel, S. ;
Bedard, P. ;
Le Tourneau, C. .
ANNALS OF ONCOLOGY, 2019, 30 (03) :385-396
[3]   Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].
Borghaei, H. ;
Paz-Ares, L. ;
Horn, L. ;
Spigel, D. R. ;
Steins, M. ;
Ready, N. E. ;
Chow, L. Q. ;
Vokes, E. E. ;
Felip, E. ;
Holgado, E. ;
Barlesi, F. ;
Kohlhaeufl, M. ;
Arrieta, O. ;
Burgio, M. A. ;
Fayette, J. ;
Lena, H. ;
Poddubskaya, E. ;
Gerber, D. E. ;
Gettinger, S. N. ;
Rudin, C. M. ;
Rizvi, N. ;
Crino, L. ;
Blumenschein, G. R. ;
Antonia, S. J. ;
Dorange, C. ;
Harbison, C. T. ;
Finckenstein, F. Graf ;
Brahmer, J. R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639
[4]   Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].
Brahmer, Julie ;
Reckamp, Karen L. ;
Baas, Paul ;
Crino, Lucio ;
Eberhardt, Wilfried E. E. ;
Poddubskaya, Elena ;
Antonia, Scott ;
Pluzanski, Adam ;
Vokes, Everett E. ;
Holgado, Esther ;
Waterhouse, David ;
Ready, Neal ;
Gainor, Justin ;
Aren Frontera, Osvaldo ;
Havel, Libor ;
Steins, Martin ;
Garassino, Marina C. ;
Aerts, Joachim G. ;
Domine, Manuel ;
Paz-Ares, Luis ;
Reck, Martin ;
Baudelet, Christine ;
Harbison, Christopher T. ;
Lestini, Brian ;
Spigel, David R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135
[5]   Hyperprogressive disease: recognizing a novel pattern to improve patient management [J].
Champiat, Stephane ;
Ferrara, Roberto ;
Massard, Christophe ;
Besse, Benjamin ;
Marabelle, Aurelien ;
Soria, Jean-Charles ;
Ferte, Charles .
NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (12) :748-762
[6]   Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1 [J].
Champiat, Stephane ;
Dercle, Laurent ;
Ammari, Samy ;
Massard, Christophe ;
Hollebecque, Antoine ;
Postel-Vinay, Sophie ;
Chaput, Nathalie ;
Eggermont, Alexander ;
Marabelle, Aurelien ;
Soria, Jean-Charles ;
Ferte, Charles .
CLINICAL CANCER RESEARCH, 2017, 23 (08) :1920-1928
[7]   Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma [J].
Chen, Robert ;
Zinzani, Pier Luigi ;
Fanale, Michelle A. ;
Armand, Philippe ;
Johnson, Nathalie A. ;
Brice, Pauline ;
Radford, John ;
Ribrag, Vincent ;
Molin, Daniel ;
Vassilakopoulos, Theodoros P. ;
Tomita, Akihiro ;
von Tresckow, Bastian ;
Shipp, Margaret A. ;
Zhang, Yinghua ;
Ricart, Alejandro D. ;
Balakumaran, Arun ;
Moskowitz, Craig H. .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (19) :2125-+
[8]   Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy [J].
Ferrara, Roberto ;
Mezquita, Laura ;
Texier, Matthieu ;
Lahmar, Jihene ;
Audigier-Valette, Clarisse ;
Tessonnier, Laurent ;
Mazieres, Julien ;
Zalcman, Gerard ;
Brosseau, Solenn ;
Le Moulec, Sylvestre ;
Leroy, Laura ;
Duchemann, Boris ;
Lefebvre, Corentin ;
Veillon, Remi ;
Westeel, Virginie ;
Koscielny, Serge ;
Champiat, Stephane ;
Ferte, Charles ;
Planchard, David ;
Remon, Jordi ;
Boucher, Marie-Eve ;
Gazzah, Anas ;
Adam, Julien ;
Bria, Emilio ;
Tortora, Giampaolo ;
Soria, Jean-Charles ;
Besse, Benjamin ;
Caramella, Caroline .
JAMA ONCOLOGY, 2018, 4 (11) :1543-1552
[9]   Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck [J].
Ferris, R. L. ;
Blumenschein, G., Jr. ;
Fayette, J. ;
Guigay, J. ;
Colevas, A. D. ;
Licitra, L. ;
Harrington, K. ;
Kasper, S. ;
Vokes, E. E. ;
Even, C. ;
Worden, F. ;
Saba, N. F. ;
Iglesias Docampo, L. C. ;
Haddad, R. ;
Rordorf, T. ;
Kiyota, N. ;
Tahara, M. ;
Monga, M. ;
Lynch, M. ;
Geese, W. J. ;
Kopit, J. ;
Shaw, J. W. ;
Gillison, M. L. .
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19) :1856-1867
[10]   Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical Trials [J].
Ferte, Charles ;
Fernandez, Marianna ;
Hollebecque, Antoine ;
Koscielny, Serge ;
Levy, Antonin ;
Massard, Christophe ;
Balheda, Rastislav ;
Bot, Brian ;
Gomez-Roca, Carlos ;
Dromain, Clarisse ;
Ammari, Samy ;
Soria, Jean-Charles .
CLINICAL CANCER RESEARCH, 2014, 20 (01) :246-252